Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology industry [3] Core Insights - The recent policy issued by the Ministry of Commerce and eight other departments aims to promote high-quality development in the pharmaceutical retail industry, which is expected to accelerate industry consolidation and benefit leading companies [6][28] - The pharmaceutical and biotechnology index has shown a year-to-date increase of 6.66%, outperforming the CSI 300 index by 5.1 percentage points [11] - The report suggests focusing on high-quality pharmacy enterprises such as Yifeng Pharmacy and Dazhenglin, as the pharmaceutical commercial sector is expected to see improved performance due to favorable policies [33] Market Performance - The pharmaceutical and biotechnology index decreased by 0.39% this week, outperforming the CSI 300 index by 0.23 percentage points, ranking 27th in industry performance [11] - Among sub-sectors, pharmaceutical commerce rose by 4.26%, while chemical pharmaceuticals fell by 1.11% [17] - The top five A-share stocks in the industry this week included *ST Changyao (+70.37%) and Hualan Biological Engineering (+32.21%) [22] Industry News and Policies - The Ministry of Commerce and other departments released an opinion on promoting high-quality development in the pharmaceutical retail industry, proposing 18 specific measures to enhance service quality and industry structure [28] - A loan interest subsidy policy for small and micro enterprises in the pharmaceutical sector was announced, aimed at encouraging investment in manufacturing [28] Company Announcements - Significant announcements include the resignation of executives at various companies and performance forecasts indicating potential losses for some firms due to price reductions and demand declines [36]

[Table_Reportdate] 2026年01月27日 [证券分析师： Table_Authors] 张季恺 S0630521110001 zjk@longone.com.cn 证券分析师： 王洋 S0630513040002 wangyang@longone.com.cn 联系人： 陈伟业 cwy@longone.com.cn 联系人： 邓尧天 dytian@longone.com.cn [晨会纪要 Table_NewTitle] 20260127 重点推荐 财经要闻 晨 会 纪 要 证券研究报告 HTTP://WWW.LONGONE.COM.CN 请务必仔细阅读正文后的所有说明和声明 [table_summary] ➢ 1.药品零售新政出台，赋能行业高质量发展——医药生物行业周报（2026/01/19- 2026/01/25） ➢ 2.2026年全球AI服务器出货同比有望增超28%，AI相关芯片涨价持续——电子行业周报 2026/1/19-2025/1/25 ➢ 1.商务部：将优化实施消费品以旧换新，促进家电等大宗耐用商品消费 ➢ 2.上期所调整白银、锡期货相关合约交易限额 ➢ 3.香港特别行政区行 ...

Group 1 - The core viewpoint is that innovative drugs are expected to show significant excess returns in 2025, driven by continuous BD overseas expansion, excellent clinical data, and policy support [1] - The CXO sector is anticipated to experience substantial growth due to the recovery in demand and improved investment environment in the global pharmaceutical industry [1] - The report emphasizes the importance of focusing on new technologies, particularly bispecific antibodies, small nucleic acid drugs, AI healthcare, and brain-computer interface innovations [3] Group 2 - Domestic supply and demand are relatively stable, with national health expenditure showing a year-on-year growth of 4.7% from January to November 2025, marking a positive turnaround after two years of decline [2] - The medical insurance fund's income and expenditure growth rates continue to decline, with total income of 2.63 trillion yuan (+2.9%) and expenditure of 2.11 trillion yuan (+0.5%) from January to November [2] - The report suggests that the commercialization of new drug forms is entering a critical phase, with significant clinical data supporting the application of B-cell depletion therapies in autoimmune diseases [3] Group 3 - Investment recommendations include focusing on innovative overseas expansion and new technology directions, with suggested stocks such as Mindray Medical, WuXi AppTec, and others [4] - The report highlights the potential for explosive growth in the global market for brain-computer interfaces, supported by policy incentives and technological breakthroughs [3]

Core Insights - The beauty industry is witnessing a shift as leading brands are refocusing on offline channels, which are expected to become a significant growth area by 2026 [1][3] - Major companies like Marubi, Proya, and Shiseido are signaling a strategic pivot towards offline sales, indicating a collective recognition of the potential profitability in this space [1][3][4] Group 1: Market Trends - The past year has seen brands expressing concerns over high competition, expensive traffic, and declining online sales, leading to a reevaluation of growth strategies [1][2] - Data from 2023-2024 shows slight increases in offline revenues for major brands, but their overall contribution to total revenue is declining, highlighting a need for strategic investment in offline channels [3][4] Group 2: Strategic Shifts - Natural堂 has demonstrated the potential of offline channels, with average annual revenues exceeding 1.6 billion yuan over the past three years, indicating that offline can still be a vital growth area [4] - The increasing costs of online traffic and the saturation of online platforms are pushing beauty brands to reconsider their channel strategies, making offline channels a more attractive option for sustainable growth [4][5] Group 3: OTC Channel Opportunities - The OTC (Over-the-Counter) channel is emerging as a key battleground for domestic brands, with over 30% of the top 100 cosmetic brands already having products displayed in pharmacies [6][7] - Major pharmacy chains are actively seeking to expand their beauty product offerings, with plans to introduce personal care items in a significant number of their stores [6][7] Group 4: Brand Strategies - Brands are adopting targeted product strategies for different channels, with Marubi launching new products specifically for offline sales and Proya entering the OTC market with a focus on medical and cosmetic synergy [8][9] - The emphasis is on creating engaging in-store experiences and building emotional connections with consumers to enhance brand loyalty and drive sales [10][11]

Core Viewpoint - The pharmaceutical sector is experiencing significant capital inflow, driven by the emergence of Nipah virus cases in India, which has heightened interest in vaccines and innovative drugs, alongside the continuous expansion of Chinese pharmaceutical companies in overseas markets [1] Group 1: Market Dynamics - On January 26, the pharmaceutical sector saw a notable increase in capital inflow, with market sentiment becoming more active due to multiple factors, including marginal improvements in industry fundamentals and supportive policies [1] - The emergence of overseas pandemic events, such as Nipah virus infections, has reignited market focus on vaccines, antiviral drugs, and public health defense systems, reinforcing long-term investment confidence in the pharmaceutical sector, particularly in innovative drugs, vaccines, and diagnostics [1] Group 2: Structural Opportunities - Recent institutional insights indicate that structural opportunities within the pharmaceutical sector are becoming clearer, with the strong momentum of innovative drugs continuing to be a core driver of the sector [1] - By January 2026, several companies, including Yilian Biotech and Rongchang Biotech, have achieved licensing agreements, validating the global competitiveness of Chinese innovative drugs, especially in cutting-edge technology areas like ADC, bispecific antibodies, and small nucleic acids [1] Group 3: Sector Developments - Progress in specific subfields is enhancing confidence in the sector, with small nucleic acid drugs showing positive clinical data in chronic hepatitis B and metabolic diseases, attracting accelerated investments from leading domestic and international companies [2] - Breakthroughs in oral immunomodulatory drugs targeting new pathways provide new treatment options for difficult diseases such as psoriasis and ulcerative colitis, warranting ongoing monitoring of related domestic companies' clinical advancements [2] - The GLP-1 class products maintain high demand in the weight loss and diabetes markets, with a gradually forming domestic pricing system and rapid overseas market expansion opening up further growth opportunities [2] Group 4: Investment Strategies - Institutions suggest investors focus on the following main lines for pharmaceutical sector investments: - Concentrate on cutting-edge areas of innovative drugs, particularly in the accelerating overseas expansion of bispecific antibodies, ADC, and small nucleic acids, such as YK Pharma and Sunlight Novo [3] - Capitalize on innovative breakthroughs in tumor therapeutic vaccines [3] - Invest in the CXO and research service industry chain that supports innovative research and development, such as Yinos and Zhaoyan New Drug [3] - Pay attention to traditional Chinese medicine and pharmacy sectors with overseas potential or high dividend defensive attributes, such as Zoli Pharmaceutical, Dong'e Ejiao, and Yifeng Pharmacy [3]

Summary of Yifeng Pharmacy Chain Conference Call Company Overview - **Company**: Yifeng Pharmacy Chain (603939.SS) - **Market Cap**: Rmb30,079 million (US$4,313 million) as of January 23, 2026 [2] Industry Insights - **Policy Change**: The release of the "Opinions on Promoting the High-Quality Development of the Pharmaceutical Retail Industry" by nine central government departments, including the Ministry of Commerce, marks a significant turning point for the pharmaceutical retail sector [1][4] - **Shift in Strategy**: The policy encourages a transition from a period of rectification to one of active support for high-quality growth and integration within the industry [1] - **Consolidation Trend**: The policy explicitly supports horizontal mergers and acquisitions among retail pharmacies and promotes vertical integration between wholesale and retail operations, which is expected to accelerate industry consolidation [4] Key Takeaways from the Policy 1. **Support for Mergers and Acquisitions**: The policy streamlines the process for transferring licenses and insurance qualifications for acquired stores, allowing original qualifications to remain active until new ones are issued [4] 2. **Prescription Outflow**: Encouragement for the flow of prescriptions from hospitals to retail pharmacies and the development of electronic prescription platforms [4] 3. **Insurance Integration**: Aims to optimize outpatient reimbursement services at designated retail pharmacies, aligning payment standards with local primary care institutions [4] 4. **Centralized Procurement**: Retail pharmacies are encouraged to participate in centralized drug procurement programs to enhance bargaining power and reduce costs [4] 5. **Remote Services**: Allows chain pharmacy headquarters to establish centralized pharmaceutical service platforms for remote prescription review and consultation by licensed pharmacists [4] 6. **New Business Models**: Supports the expansion of services to include health consulting and management, and encourages brand-name chains to establish a presence in communities [5] Financial Outlook - **Target Price**: Rmb32.00 per share, derived from DCF analysis with a terminal growth rate of 3% and a WACC of 11.5% [6] - **Valuation Metrics**: Attractive valuation at 16x 2026E PE, with a strong cash position of over Rmb8 billion as of Q3 2025 [1] Investment Recommendation - **Rating**: Maintain Buy rating on Yifeng Pharmacy, positioned to capitalize on the consolidation trend [1] - **Expected Returns**: Anticipated share price return of 29.0% and expected total return of 32.0% [2] Risks - **Key Risks**: 1. Lower-than-expected growth due to slower pharmacy network penetration [7] 2. Unfavorable policies regarding prescription outflow [7] 3. Low-quality M&A activity that fails to generate synergies [7] Conclusion Yifeng Pharmacy Chain is well-positioned to benefit from the supportive policy environment and industry consolidation, with a strong financial foundation and attractive valuation metrics. The investment outlook remains positive, although potential risks must be monitored closely.

上周五指数尾盘震荡拉升，深成指探底回升，创业板指、深成指均涨超0.5%，北证50指数大涨超3%。 沪深两市成交额3.09万亿，较上一个交易日放量3935亿。盘面上，市场热点快速轮动，全市场超3900只 个股上涨，其中121只个股涨停。从板块来看，光伏概念爆发，隆基绿能、钧达股份、协鑫集成、明阳 智能、拓日新能等30余股涨停。商业航天概念反复活跃，十余只成分股涨停，金风科技、润贝航科、西 部材料涨停。AI应用概念走高，浙文互联4天2板。贵金属概念延续强势，白银有色4连板，中国黄金、 豫光金铅涨停。医药商业概念表现活跃，益丰药房涨停。下跌方面，保险、银行板块跌幅居前。截至收 盘，沪指涨0.33%，深成指涨0.79%，创业板指涨0.63%。 在今日券商晨会上，中信建投认为，景气为纲，坚守"科技+资源品"双主线；东方财富认为，产业主题 与涨价链共舞下的春季行情；华泰证券认为，金价破五千、银价破一百的启示。 中信建投：景气为纲，坚守"科技+资源品"双主线 近两周市场资金面有所分化，宽基ETF资金流出超过5700亿元，而行业主题型ETF仍有1100亿元左右的 资金流入。总体来说，近期主动降温调控节奏，整体大基调仍然积极， ...

Core Viewpoint - The joint issuance of the "Opinions on Promoting High-Quality Development of the Pharmaceutical Retail Industry" by nine departments aims to enhance the industry through 18 measures focusing on mergers and acquisitions, service transformation, and regulatory optimization [1] Group 1: Industry Impact - The "Opinions" are expected to accelerate the outflow of hospital prescriptions, contributing to growth in the pharmaceutical retail sector [1] - The document encourages horizontal mergers and acquisitions among retail pharmaceutical companies, aiming to optimize the business environment and streamline the licensing process for integrated stores [1][2] - The number of pharmacies in China is projected to decline, with a total of 686,426 stores by the end of Q3 2025, marking a reduction of nearly 20,000 stores since Q4 2024 [2] Group 2: Market Opportunities - The rapid exit of small and medium-sized pharmacies creates market opportunities for leading companies to consolidate and expand their market share through mergers and acquisitions [2] - The "Opinions" promote the transformation of pharmacies from mere sales points to health service hubs, providing new growth avenues for listed pharmacies facing revenue stagnation [2] Group 3: Compliance and Management - Regulatory changes are pushing for a shift towards digital and preventive oversight, enhancing compliance advantages for listed pharmacies compared to smaller competitors [3] - Companies like Yifeng Pharmacy have demonstrated significant profit growth through refined management and compliance, with a 10.27% increase in net profit year-on-year for the first three quarters of 2025 [3] - The core competitiveness of retail pharmacies is increasingly seen in their professional capabilities, with companies developing comprehensive pharmaceutical service systems [3][4]

Regulatory Actions - The China Securities Regulatory Commission (CSRC) is intensifying its crackdown on illegal fundraising, misappropriation, self-financing, and profit transfer in the private equity fund sector, holding violators accountable [1] - In 2025, the CSRC organized 17,500 institutions for self-assessment and problem rectification, taking administrative measures against over 600 entities and individuals, and initiating about 30 investigations [1] Market Developments - The Shanghai Futures Exchange announced adjustments to the price limits and margin requirements for nickel and other futures contracts, effective January 27, 2026 [2] - The futures price limit for nickel contracts will be set at 10%, while the margin for general positions will be 12% [2] Banking and Financial Products - By the end of 2025, the total scale of bank wealth management products reached 33.29 trillion yuan, an increase of 11.15% from the beginning of the year [3] - The average yield of wealth management products in 2025 was 1.98%, with total returns for investors amounting to 730.3 billion yuan, a 2.87% increase year-on-year [3] Commodity Prices - International gold prices have surged, with the price of gold jewelry exceeding 1,500 yuan per gram, reaching a record high of 1,548 yuan per gram on January 23 [4] - The price of silicon materials is expected to face downward pressure due to high inventory levels and reduced demand from downstream sectors [4] Corporate Announcements - Ideal Auto plans to close some underperforming stores as part of its operational assessment [5] - Anqi Yeast's subsidiary plans to invest 222 million yuan in a green manufacturing project for yeast products, expected to start construction in August 2026 [9] - Lisheng Pharmaceutical forecasts a net profit increase of 116.77% to 138.44% for 2025, estimating profits between 400 million and 440 million yuan [10] - Yingboer anticipates a net profit growth of 139.43% to 167.6% for 2025, projecting profits between 170 million and 190 million yuan [11] Stock Market Performance - The Shenzhen Composite Index rose by 0.79%, with over 3,900 stocks increasing in value, and more than 121 stocks hitting the daily limit [18] - The photovoltaic sector saw significant gains, with multiple stocks reaching their daily limit [18]

Core Viewpoint - The recent policy document issued by multiple government departments aims to promote high-quality development in the pharmaceutical retail industry, leading to a surge in stock prices of major pharmacy chains in the A-share market [1][3]. Group 1: Policy Measures - The policy document outlines 18 specific measures to enhance the pharmaceutical retail sector, focusing on professionalization, digitalization, and regulatory compliance [1]. - Key initiatives include improving pharmacy service capabilities, supporting mergers and acquisitions among retail pharmacies, and fostering a fair competitive market environment [2]. Group 2: Market Impact - The policy is expected to drive mergers and acquisitions, increasing industry concentration and facilitating the transition of pharmacies from "drug sales" to "comprehensive services" [2]. - Leading pharmacy chains such as Yifeng Pharmacy and Dacelins have seen significant stock price increases, with Yifeng's store count projected to exceed 14,666 by September 2025, and Dacelins operating 17,385 stores [3]. Group 3: Benefits to Other Companies - Other pharmaceutical companies like Shanghai Pharmaceuticals, China Resources Pharmaceutical, and Jiuzhoutong are anticipated to benefit from the integration of wholesale and retail operations, enhancing their revenue potential [3]. - The policy encourages retail pharmacies to enhance their service capabilities, which may benefit digital and supply chain service providers in the healthcare sector [4].